Jennifer Ellis

Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.

Alliance Pharmaceutical Corp. is a research & development company, which focused on transformed innovative scientific discovered into novel therapeutic and diagnostic agents. It currently focused on developed its lead product, Oxygent, an intravascular oxygen carrier designed to augment oxygen deliveryed in surgical patients. The company was founded by Duane J. Roth in 1983 and is headquartered in San Diego, CA.